Cargando…

Observational study on time on treatment with abiraterone and enzalutamide

INTRODUCTION: The aim of this study was to assess time on treatment with abiraterone and enzalutamide, two androgen receptor targeted (ART) drugs, the impact on time on treatment of time interval without drug supply between prescription fillings, and adherence to treatment. MATERIAL AND METHODS: By...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fallara, Giuseppe, Lissbrant, Ingela Franck, Styrke, Johan, Montorsi, Francesco, Garmo, Hans, Stattin, Pär
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769419/ https://www.ncbi.nlm.nih.gov/pubmed/33370378 http://dx.doi.org/10.1371/journal.pone.0244462

Ejemplares similares

Population-based study on use of chemotherapy in men with castration resistant prostate cancer
por: Lissbrant, Ingela Franck, et al.
Publicado: (2013)

The Value of Real-World Data in Understanding Prostate Cancer Risk and Improving Clinical Care: Examples from Swedish Registries
por: Beckmann, Kerri, et al.
Publicado: (2021)

Mini Review on the Use of Clinical Cancer Registers for Prostate Cancer: The National Prostate Cancer Register (NPCR) of Sweden
por: Cazzaniga, Walter, et al.
Publicado: (2019)

Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic
por: Gedeborg, Rolf, et al.
Publicado: (2021)

Comparison of Relative Survival and Cause-Specific Survival in Men With Prostate Cancer According to Age and Risk Category: A Nationwide, Population-Based Study
por: Orrason, Andri Wilberg, et al.
Publicado: (2021)

A drug comorbidity index to predict mortality in men with castration resistant prostate cancer
por: Fallara, Giuseppe, et al.
Publicado: (2021)

Comparative Effectiveness of Different Radical Radiotherapy Treatment Regimens for Prostate Cancer: A Population-Based Cohort Study
por: Pettersson, Andreas, et al.
Publicado: (2020)

Susceptibility to SARS‐Cov‐2 infection and risk for severe COVID‐19 in patients with prostate cancer on androgen deprivation therapy
por: Gedeborg, Rolf, et al.
Publicado: (2022)

Public online reporting from a nationwide population‐based clinical prostate cancer register
por: Stattin, Pär, et al.
Publicado: (2018)

Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
por: Fallara, Giuseppe, et al.
Publicado: (2023)

Diagnostic activity impacts lifetime risk of prostate cancer diagnosis more strongly than life expectancy
por: Orrason, Andri Wilberg, et al.
Publicado: (2022)

Population‐based study of long‐term functional outcomes after prostate cancer treatment
por: Carlsson, Sigrid, et al.
Publicado: (2015)

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
por: Gurioli, Giorgia, et al.
Publicado: (2020)

Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation
por: Wright, Timothy C., et al.
Publicado: (2021)

Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?
por: Chen, Ming-kun, et al.
Publicado: (2022)

Use of Antiepileptic Drugs and Risk of Prostate Cancer: A Nationwide Case-Control Study in Prostate Cancer Data Base Sweden
por: George, Gincy, et al.
Publicado: (2023)

Long-term Outcomes Among Men Undergoing Active Surveillance for Prostate Cancer in Sweden
por: Ventimiglia, Eugenio, et al.
Publicado: (2022)

Cardiovascular toxicities associated with abiraterone compared to enzalutamide–A pharmacovigilance study
por: Cone, Eugene B., et al.
Publicado: (2021)

Use of Warfarin or Direct Oral Anticoagulants and Risk of Prostate Cancer in PCBaSe: A Nationwide Case-Control Study
por: Parker, Jonathan, et al.
Publicado: (2020)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

Androgen Deprivation Therapy and the Risk for Inguinal Hernia: An Observational Nested Case Control Study
por: Hermann, Maria, et al.
Publicado: (2021)

Androgen deprivation therapy and excess mortality during the COVID-19 pandemic
por: Stattin, P., et al.
Publicado: (2021)

Frequency of Biopsy and Tumor Grade Before vs After Introduction of Prostate Magnetic Resonance Imaging
por: Robinson, David, et al.
Publicado: (2023)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
por: Talwar, Harkirat Singh
Publicado: (2021)

Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review
por: Shah, Yash B., et al.
Publicado: (2022)

Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment
por: Mei, Zejie, et al.
Publicado: (2022)

Long-term adverse effects after curative radiotherapy and radical prostatectomy: population-based nationwide register study
por: Fridriksson, Jón Ö., et al.
Publicado: (2016)

Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
por: Cheng, Heather H., et al.
Publicado: (2015)

Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients
por: Liontos, Michalis, et al.
Publicado: (2021)

Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide
por: Nakai, Yasushi, et al.
Publicado: (2018)

Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients
por: Kulkarni, A.A., et al.
Publicado: (2021)

Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
por: Rana, Dikshyanta, et al.
Publicado: (2021)

Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan
por: Li, Pei-Yu, et al.
Publicado: (2022)

Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein
por: Zhang, Ying, et al.
Publicado: (2022)

Population-based study of long-term anticoagulation for treatment and secondary prophylaxis of venous thromboembolism in men with prostate cancer in Sweden
por: Balabanova, Yanina, et al.
Publicado: (2022)

Risk of Fractures and Falls during and after 5-α Reductase Inhibitor Use: A Nationwide Cohort Study
por: Robinson, David, et al.
Publicado: (2015)

Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide
por: Lin, Yi-Ting, et al.
Publicado: (2021)

Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
por: Antonarakis, Emmanuel S., et al.
Publicado: (2023)

Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide
por: Belic, Jelena, et al.
Publicado: (2018)

Physician Dispensing Among Urology Practices and the Use of Abiraterone or Enzalutamide for Men With Advanced Prostate Cancer
por: Lai, Lillian Y, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_726aed4f9f7i05sndldpgpfq7d